Compare Amphastar Pharmaceuticals Inc (AMPH) vs Crowdstrike Holdings Inc (CRWD) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

CrowdStrike (CRWD) trades at $187.18, down 5.66% in the last session, following its recent 4-for-1 stock split. The stock exhibits a bullish technical trend with strong moving average signals, though RSI levels suggest overbought conditions. Fundamentally, the company shows robust revenue growth, reaching $3.95 billion in 2025, and has beaten earnings estimates for three consecutive quarters. However, valuation multiples remain elevated with a P/E of 765.02, and net income margins are negative. Analyst sentiment is overwhelmingly positive, with 76% recommending a buy.

The outlook for CRWD is supported by strong demand in AI-driven cybersecurity, but high valuation and intense competition pose risks. Revenue growth acceleration and market leadership in zero-trust security present opportunities, though profitability challenges and premium pricing require careful monitoring. The consensus price target of $184.40 suggests limited near-term upside from current levels, indicating a balanced risk-reward profile for investors.